| Literature DB >> 35578648 |
Lenka Koklesova1, Alena Mazurakova1, Marek Samec2, Erik Kudela1, Kamil Biringer1, Peter Kubatka3, Olga Golubnitschaja4.
Abstract
Mitochondria are the "gatekeeper" in a wide range of cellular functions, signaling events, cell homeostasis, proliferation, and apoptosis. Consequently, mitochondrial injury is linked to systemic effects compromising multi-organ functionality. Although mitochondrial stress is common for many pathomechanisms, individual outcomes differ significantly comprising a spectrum of associated pathologies and their severity grade. Consequently, a highly ambitious task in the paradigm shift from reactive to predictive, preventive, and personalized medicine (PPPM/3PM) is to distinguish between individual disease predisposition and progression under circumstances, resulting in compromised mitochondrial health followed by mitigating measures tailored to the individualized patient profile. For the successful implementation of PPPM concepts, robust parameters are essential to quantify mitochondrial health sustainability. The current article analyses added value of Mitochondrial Health Index (MHI) and Bioenergetic Health Index (BHI) as potential systems to quantify mitochondrial health relevant for the disease development and its severity grade. Based on the pathomechanisms related to the compromised mitochondrial health and in the context of primary, secondary, and tertiary care, a broad spectrum of conditions can significantly benefit from robust quantification systems using MHI/BHI as a prototype to be further improved. Following health conditions can benefit from that: planned pregnancies (improved outcomes for mother and offspring health), suboptimal health conditions with reversible health damage, suboptimal life-style patterns and metabolic syndrome(s) predisposition, multi-factorial stress conditions, genotoxic environment, ischemic stroke of unclear aetiology, phenotypic predisposition to aggressive cancer subtypes, pathologies associated with premature aging and neuro/degeneration, acute infectious diseases such as COVID-19 pandemics, among others.Entities:
Keywords: Bioenergetic health index; COVID-19; Cell apoptosis; Disease development; Disease severity; Health; Health policy; Ischemia–reperfusion; Ischemic stroke; Mitochondria; Mitochondrial fusion and fission; Mitochondrial health index; Mitochondrial stress; Predictive preventive personalized medicine (PPPM/3PM); Primary secondary tertiary care; Systemic effects
Year: 2022 PMID: 35578648 PMCID: PMC9096339 DOI: 10.1007/s13167-022-00281-6
Source DB: PubMed Journal: EPMA J ISSN: 1878-5077 Impact factor: 8.836
Fig. 1Formula for MHI calculation. Enzymes occurring in ETC: NADH–coenzyme Q reductase (complex I), succinate–coenzyme Q reductase/succinate dehydrogenase (complex II), coenzyme QH2 cytochrome-c reductase (complex III), cytochrome-c oxidase (complex IV), and ATP synthase (complex V). Enzymes occurring in TCA cycle: citrate synthase, aconitase, isocitrate dehydrogenase, α-ketoglutarate, succinyl-CoA synthetase, succinate dehydrogenase, fumarase, and malate dehydrogenase. Abbreviations: mtDNA, mitochondrial DNA; TCA, tricarboxylic acid; NADH, nicotinamide adenine dinucleotide; FADH2, flavin adenine dinukleotide; CO2, carbon dioxide; Cyt c, cytochrome c; CoQ, coenzyme Q; ADP, adenosine diphosphate; ATP, adenosine triphosphate; GTP, guanosine triphosphate; ETC, electron transport chain; CoA, coenzyme A
Fig. 2Formula for BHI calculation. These results can be detected in mitochondrial stress test by using of various modulators affecting the mitochondrial respiration: oligomycin (complex V inhibitor), carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) (oxygen consumption by complex IV reaches the maximum), and mixture of rotenone (complex I inhibitor) and antimycin A (complex III inhibitor) [52]
Altered MHI or BHI in clinically relevant pathologic conditions
| Disease | Study design | Altered MHI or BHI | Results | Reference |
|---|---|---|---|---|
| Cardiac surgery | Healthy adult donors ( | ↓ BHI | ↓ basal, ATP-linked, proton leak, ↓ maximal mitochondrial oxygen consumption rate, ↓ reserve capacity, ↓ mitochondrial membrane potential, ↑ ROS | [ |
| Prostate cancer | RWPE-1, WPE1-NA22, WPE1-NB14, WPE1-NB11 and WPE1-NB26 cell lines | ↓ MOBI | Invasive prostate cancer cells: ↓ OXPHOS, ↑ glycolysis, ↓ reserve capacity, ↑ oxygen consumption rate, ↓ extracellular acidification rate | [ |
| Diabetic nephropathy | Peripheral blood mononuclear cells from healthy controls ( | ↓ BHI | ↓ reserve capacity, ↓ maximal respiration, ↓ metabolic flexibility | [ |
| Caregiving stress | Peripheral blood mononuclear cells from healthy mothers of a child with an autism spectrum disorder (high-stress caregivers, | ↓ MHI | ↑ perceived stress, ↓ positive mood, ↑ negative daily affect, ↓ mitochondrial content of citrate synthase and mtDNA copy number, followed succinate dehydrogenase and COX | [ |
Abbreviations: ↑ = increased; ↓ = decreased
MHI, mitochondrial health index; BHI, bioenergetic health index; MOBI, mitochondrial oncobioenergetic index; mtDNA, mitochondrial DNA; ROS, reactive oxygen species; ATP, adenosine triphosphate; COX, cyclooxygenase
Fig. 3MHI and BHI in health and disease. Abbreviations: mtDNA, mitochondrial DNA; MHI, mitochondrial health index; BHI, bioenergetic health index; OXPHOS, oxidative phosphorylation; ATP, adenosine triphosphate
Altered mtDNA copy numbers, mitochondrial enzymatic activities, and bioenergetic pathways in clinically relevant conditions
| Disease | Study design | Results | Supposed MHI or BHI alteration | Reference |
|---|---|---|---|---|
| Cardiomyopathy | Colon and heart tissue from mice carrying the heteroplasmic m.5024C > T mutation in the mitochondrial tRNA alanine (tRNAAla) gene (C5024T mice) | ↑ mtDNA copy number, ↑ | ↓ MHI | [ |
| Heart failure | C57BL/6 J transgenic mice overexpressing human TFAM or murine Twinkle | ↑ TFAM, ↑ Twinkle helicase, ↑ mtDNA copy number, ↓ mitochondrial oxidative stress, ↑ cardioprotection | ↑ MHI | [ |
| Heart failure | Cultured cardiomyocytes | ↑ apoptotis, ↑ caspase-3, ↑ heart failure progression, ↑ mitochondrial dysfunction, dysregulation of cellular energy metabolism, ↑ endothelin 1 | ↓ MHI | [ |
| Non-surgical bleeding in heart failure | Multiple blood samples from patients with heart failure: bleeder (n = 12) and non-bleeder (n = 19) groups | ↑ ROS, ↑ oxidative stress, ↑ oxidized low-density lipoproteins, ↑ apoptosis, ↑ Bax, ↑ cytochrome c release, ↓ total antioxidant capacity, ↓ Bcl-2, ↓ Bcl-xL, | ↓ MHI | [ |
| Hypoplastic left heart syndrome with early heart failure | Induced pluripotent stem cell–derived cardiomyocytes from patients with hypoplastic left heart syndrome with early heart failure | ↑ apoptotic signaling, ↑ redox stress, ↑ uncompensated oxidative stress, ↑ mitochondrial respiration defects, ↑ mitochondrial permeability transition pore opening, ↓antioxidant response | ↓ MHI | [ |
| Decompensated chronic primary mitral regurgitation | Left ventricular endomyocardial biopsies (n = 12) from normal hearts (n = 5), patients with compensated (n = 6) and decompensated (n = 6) chronic primary mitral regurgitation | ↑ natriuretic peptide A, ↑ cell survival genes, ↑ extracellular matrix genes, ↓ | ↓ MHI, ↓ BHI | [ |
| Cardiac ischemia–reperfusion injury | Cardiac-specific PGAM5 knockout (PGAM5CKO, PGAM5f/f, α-MHCCre +) mice | ↑ PGAM5, ↓ mtDNA copy number, ↑ necroptosis, ↓ state-3/4 respiration | ↓ MHI | [ |
| ST-segment elevation myocardial infarction | Peripheral blood was obtained from patients ( | ↑ HtrA2, ↑ apoptosis | ↓ MHI | [ |
| Cardiac ischemia–reperfusion injury | Right atrial and left ventricular biopsies from patients scheduled for elective coronary artery bypass: treadmill exercise group ( | ↓ mitochondrial respiration, ↑ cardiac troponin T, ↑ apoptosis, ↑ caspase-3, ↑ perioperative damage of mitochondria and myocardium | ↓ MHI | [ |
| Cardiac ischemia–reperfusion injury | Male C57BL/6 mice with ischemia–reperfusion injury | ↑ miR-205, ↑ infarct size, ↑ oxidative stress, ↑ mitochondrial dysfunction, ↑ apoptosis | ↓ MHI | [ |
| Ischemia–reperfusion-induced brain injury | Rat middle cerebral artery occlusion stroke and oxygen–glucose deprivation followed by reoxygenation model | ↑ RTN1-C, ↑ endoplasmic reticulum stress, ↑ apoptosis, ↓ mitochondrial Bcl-xL, ↑ cytosolic Bcl-xL, | ↓ MHI | [ |
| Ductal invasive breast adenocarcinomas, gastric adenocarcinomas, and squamous oesophageal and lung carcinomas | Frozen tissue sections from human biopsies of untreated patients with primary ductal invasive breast adenocarcinomas, gastric and prostate adenocarcinomas, and squamous oesophageal and lung carcinomas | ↓ OXPHOS markers: ↓ β-F1-ATPase, ↓ hsp60, ↑ glycolytic markers: ↑ GAPDH, ↑ pyruvate kinase | ↓ BHI | [ |
| Hyperthermia treatment for colon cancer | SW480 and Pt.93 colon cancer cells exposed to 32 °C, 37 °C and 42 °C for 60 min | ↑ proton leak, ↑ non-glycolytic acidification, ↑ glycolysis, ↑ glycolytic capacity, ↑ glycolytic reserve | ↓ BHI | [ |
| COVID‐19 pneumonia | Peripheral blood monocytes from patients with COVID‐19 pneumonia ( | ↓ basal and maximal respiration, ↓ spare respiratory capacity, ↓ proton leak, abnormal mitochondrial ultrastructure, depolarized mitochondria | ↓ BHI | [ |
| Alzheimer’s disease | Immortalized hippocampal astrocytes from 3xTg-AD mice | ↑ ROS production, ↓ glycolysis, ↓ mitochondrial oxygen consumption, deregulations of endoplasmic reticulum functions, Ca2+ homeostasis, and protein synthesis | ↓ BHI | [ |
| APP/PS1 transgenic mice | ↑ methylation | ↓ MHI | [ | |
| Renal injury in human hypertension | Blood and urine samples from essential ( | ↑ copy numbers of mtDNA genes | ↓ MHI | [ |
| Diabetic kidney disease | Serum, peripheral blood mononuclear cells and kidney biopsy specimens from healthy controls ( | ↓ copy numbers of mtDNA, ↑ mtDNA damage, ↑ dihydroxyacetone phosphate, ↑ succinyl-CoA synthetase, ↑ ROS, ↑ apoptosis, ↓ mitochondrial membrane potential | ↓ MHI | [ |
| Pediatric chronic overlapping pain conditions with functional gastrointestinal disorders | Peripheral blood mononuclear cells from children aged 10–18 years with chronic overlapping pain conditions patients ( | ↓ OXPHOS, ↓ ATP production, ↓ basal respiration, ↓ ATP-linked oxygen consumption, ↓ glycolysis, ↓ extracellular acidification rate, ↑ spare respiratory capacity | ↓ BHI | [ |
| Obesity-associated kidney injury | Age- and sex-matched healthy volunteers ( | ↑ urinary mtDNA copy number of nicotinamide adenine dinucleotide dehydrogenase subunit-1, after bariatric surgery: ↓ urinary mtDNA copy number of nicotinamide adenine dinucleotide dehydrogenase subunit-1 | ↓ MHI | [ |
| Porphyria | peripheral blood mononuclear cells from porphyria patients ( | ↓ oxygen consumption rate, ↓ basal, ↓ ATP-linked, ↓ proton leak, ↓ maximal, ↓ reserve, and ↓ non-mitochondrial respiration, ↑ oxidative stress, ↑ calcium cycling, ↓ mitochondrial ATP generation | ↓ BHI | [ |
| Yoga practice in patients with rheumatoid arthritis | Total participants with rheumatoid arthritis ( | ↑ mtDNA copy numbers, ↑ | ↑ MHI | [ |
| Oocyte’s vitrification | Collected metaphase II oocytes ( | In vitrified oocytes: ↓ mtDNA copy number, ↓ COX, ↓ | ↑ MHI | [ |
Abbreviations: ↑ = increased; ↓ = decreased
MHI, mitochondrial health index; BHI, bioenergetic health index; TFAM, human transcription factor A of mitochondria; mtDNA, mitochondrial DNA; PGAM5, phosphoglycerate mutase 5; ROS, reactive oxygen species; ATP, adenosine triphosphate; hsp60, heat-shock protein 60; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CYTB, mitochondrial cytochrome b; COX, cyclooxygenase; COX-2, cytochrome c oxidase 2; COX-3, cytochrome c oxidase 3; Ca, calcium cation; AMPK, 5′ adenosine monophosphate-activated protein kinase; TIMP-1, tissue inhibitor of matrix metalloproteinases 1; KLOTHO, a Greek word for the gene that regulates lifespan; NAD + , nicotinamide adenine dinucleotide; Bcl-2, B-cell lymphoma 2; Bcl-xL; B-cell lymphoma-extra large; Bax; BCL2 associated X; SERCA2, sarcoplasmic/endoplasmic reticulum calcium ATPase 2; JUN, Jun proto-oncogene, AP-1 transcription factor subunit; MAPK, mitogen-activated protein kinase, ATP5A1, mitochondrial membrane ATP synthase; PRDX3, peroxiredoxin 3; FAS, Fas cell surface death receptor; PDCD1, programmed cell death protein 1; HtrA2, HtrA serine peptidase 2; RTN1-C, reticulon protein 1-C; miR-205, micro RNA 205